US equities |
NVDA $243.15 ▲+1.78% SPCX $174.36 ▲+1.91% MU $1,061.52 ▼-0.23% AMD $642.75 ▲+1.74% META $741.00 ▼-0.12% MRVL $279.87 ▲+3.18% SNDK $1,694.62 ▼-0.56% AMZN $251.35 ▼-0.02%
FinancialContent

Opus Genetics, Inc. - Common Stock (NQ:IRD)

4.420 +0.040 (+0.91%)
Delayed Quote Updated: 9:31 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Opus Genetics, Inc. - Common Stock

Unusual volume stocks are being observed in Thursday's session. ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)... 
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
News headline image
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst ↗
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within... 
Via MarketBeat
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review ↗
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy. 
Via Benzinga
News headline image
Viatris Eye Drops Data Shows Promise For Blurred Near Vision ↗
Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Unusual volume stocks in Tuesday's session ↗
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
News headline image
Power Metallic Mines Inc. (TSXV: PNPN) (OTCQB: PNPNF): A Strategic Entry Point for Investors? More Stocks Inside
Via AB Newswire
Topics Electric Vehicles
News headline image
Discover the top movers in Friday's pre-market session. ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga